CLOSE

 

IEO Radiotherapy

 

IEO Advanced Radiotherapy Centre ARC

among the top 10 in the world for treatment, 

research and technology

 

 WHY IEO HIGH PRECISION RADIOTHERAPY

  

  • Personalised Target Radiotherapy
  • About 65 employees (radiation oncologists, radiotherapy technicians, medical physicists, nurses) + students, residents, research fellows, biomedical engineers (Politecnico of Milan)
  • Residency Program in Radiation Oncology of the University of Milano
  • Latest equipment for high precision radiotherapy: 

                                       - 6 Linacs for  Image-guided Radiation Therapy-Intensity Modulated Radiation Therapy  (IGRT, IMRT) and Stereotactic                                                            Radiotherapy (SRT) 

                                      - 2 Linacs for Intraoperative radiation therapy

                                      - 5 Systems for brachytherapy (HDR, PDR, Iodine)                                                                               

                                      - Last generation Treatment Planning Systems

                                      - 2 CT scans (4-D) and link to MRI (1.5 & 3 T) and PET scan

 

  • Numerous international and national research programs 
  • 35 full papers/year, IF of about 150
  • HIGH PRECISION RADIOTHERAPY ADVANTAGES

    • Pain-freeVERO
    • Non-invasive
    • No anesthesia required
    • Out-patient procedure
    • No recovery time
    • Immediate return to normal activity
    • Exceptional accuracy spares healthy tissue and organs
    • No breath holding or “respiratory gating” required  during treatment
    • No invasive head or body frame
  • IEO EXPERIENCE IN NUMBERS

    2012: 3287 new patients

    2013: 3366 new patients

    2014:  about 3281 new patients

     
    • Numbers
    1. 46%      Breast cancer                  
    2. 22%      Oligometastatic/recurrent cancer                           
    3. 8%        Prostate cancer                     
    4. 6%       Head and neck cancer  
    5. 4%       Thorax cancer     
    6. 4%       Gastrointestinal cancer
    7. 3%        Gynecological cancer    
    8.              Other tumors   

PARTNERSHIP

Università degli Studi di Milano

MAIN CREDITS

Ministero della Salute Joint Commission International bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153 - Codice intermediario fatturazione elettronica: A4707H7

IRCCS - ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO